Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-05-22

FDA Approved: UROXATRAL — Supplemental Application (Advanz Pharma (US) Corp.)

View source ↗

Summary

The FDA approved a supplemental application for UROXATRAL (alfuzosin HCl) submitted by Advanz Pharma (US) Corp.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Uroxatral (Alfuzosin)

Snippet

SUPPL AP for UROXATRAL (ALFUZOSIN HCL)